Animal experiments confirm that treatment with dapagliflozin in the doxorubicin-induced DCM mice model significantly improved the depressed LVEF and fractional shortening (FS) and decreased left ventricular internal dimensions at end-diastole (LVIDd) and end-systole (LVIDs).[12] The clinical practice of patients with DCM treated with SGLT2 inhibitors are not well validated. Here, SLC5A2 is linked to familial dilated cardiomyopathy.